Article · Volume 3, Issue 2 · pp. 98–104
Pharmacotherapy for multidrug resistant tuberculosis
Naveen Chhabra1, M. L. Aseri1, Ramakant Dixit2, S. Gaur1
- 1Departments of Pharmacology, College, Ajmer, Rajasthan, India Educational Forum.
- 2Respiratory Medicine, J. L. N. Medical College, Ajmer, Rajasthan, India Educational Forum.
Abstract
The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR- TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB.
Keywords: Cycloserine; ethionamide; kanamycin; multidrug resistance tuberculosis; para-aminosalicylic acid
The full text of this article is available as a PDF. Open the PDF.